


INTRODUCTION

Significant delays between tissue acquisition, molecular testing, and drug availability often force clinicians to initiate platinum-based chemotherapy as a bridge before EGFR-directed therapy.

METHODS

Design:



DISCUSSION AND CONCLUSION

Actionable Take Away Message

- Access matters
- Bridge when necessary
- Test when possible
- Adapt to reality
- Improve equity

Future Direction for Research

- Validate empiric osimertinib strategies after EGFR-TKI progression when T790M testing is unavailable or inconclusive.

REFERENCES & ACKNOWLEDGEMENTS

1. Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med.* 2017;376:629–640.
2. Ramalingam SS, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N Engl J Med.* 2020;382:41–50.

We thank our patients and their families, and the medical, nursing, laboratory, and supportive care teams of the Oncology Department, Abderrahmen Mami Hospital, for their contribution to patient care and this study.



*All authors responsible for content disclose that AI was NOT used in the development of the material .

RESULTS



Figure 1 : Patient Treatment Pathway

- Median age : 62 years.
- 10 Female & 9 Male
- 13 : current or former smokers.
- Del 19 : 17
- Median PFS on Erlotinib : 13 months (6-36).
- Tissue re-biopsy was NOT performed in 15 patients.
- Median follow up from Osimertinib initiation was 6 months.




Figure 2 : Response to Empiric Osi